Clinical trial · Observational
Cancer Survivor Cardiomyopathy Detection
CAncer Survivor CArdiomyopathy DEtection Pilot Study
NCT05201014CI-TRIAL-00121222CASCADEterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): diminished funding
Summary
Brief summary (as posted)
The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cardiovascular Diseases | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Echocardiogram | Diagnostic Test | — | UNRESOLVED |
| Electrocardiogram | Diagnostic Test | — | UNRESOLVED |
| NT-pro-BNP | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1 year follow-up
- description
- patients who were treated in the year before and are now returning for their 1-year follow-up.
- interventionNames
- Diagnostic Test: NT-pro-BNP
- Diagnostic Test: Electrocardiogram
- Diagnostic Test: Echocardiogram
- label
- Prior to anthracycline-based therapy
- description
- patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
- interventionNames
- Diagnostic Test: NT-pro-BNP
- Diagnostic Test: Electrocardiogram
- Diagnostic Test: Echocardiogram
Primary outcomes (3)
- measure
- Diagnostic performance of AI-ECG for left ventricular ejection fraction (LVEF) < 50%
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years of age prior to enrollment and anthracycline start date * Diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure. * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same Exclusion Criteria: * LVEF \<50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same. * Individuals with pacemakers, defibrillators, or other implanted electronic devices * Inability/unwillingness of individual to give written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.